Targeting triple-negative breast cancer: optimising therapeutic outcomes.

  title={Targeting triple-negative breast cancer: optimising therapeutic outcomes.},
  author={Karen A. Gelmon and Rebecca Dent and John R. Mackey and Kara Laing and Deanna Mcleod and Sunil Verma},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  volume={23 9},
BACKGROUND Triple-negative breast cancer (TNBC) is a distinct subset of breast cancer (BC) defined by the lack of immunohistochemical expression of the estrogen and progesterone receptors and human epidermal growth factor receptor 2. It is highly heterogeneous and displays overlapping characteristics with both basal-like and BC susceptibility gene 1 and 2 mutant BCs. This review evaluates the activity of emerging targeted agents in TNBC. DESIGN A systematic review of PubMed and conference… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS
65 Citations
132 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 65 extracted citations


Publications referenced by this paper.
Showing 1-10 of 132 references

overall survival results from a double-blind, randomized, placebocontrolled, phase 2b trial

  • S Bondarde, V Kaklamani, cancer Prasad Sahoo T et al. Sorafenib in combination wit breast
  • Cancer Res 2010; 70:
  • 2010
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…